Effects Of Choroidal Vascular Hyperpermeability On The Treatment Of Polypoidal Choroidal Vasculopathy With Conbercept

Objective: To evaluate the effect of choroidal vascularhyperpermeability,as determined using indocyanine green angiography(ICGA),on the outcome of anti–vascular endothelial growth factor(VEGF)treatment for polypoidal choroidal vasculopathy(PCV).Methods: A prospective analysis was performed on patients diagnosed with PCV in the outpatient department of Ningxia Eye Hospital from December,2018 to December,2019.There were 22 cases with 22 eyes,among which the age ranged from 57 to 83 years.They were divided into two groups according to ICGA.Among them,11 cases(male 5 female 6)were positive for choroidal vascular hyperpermeability in group A and 11 cases(male 6female 5)were negative for choroidal vascular hyperpermeability in group B.Both group A and B were treated with intravitreal injection of conbercept and 3+PRN(Pro-re-nata).After the first three injections,all the affected eyes were followed up for a total of 9 months.The best corrected visual acuity(BCVA)and central retinal thickness(CRT)were recorded at baseline,3rd,6th and 9th month after treatment,and the effect of choroidal vascular hyperpermeability on the treatment of polypoid choroidal vascalopathy by conbercept was analyzed.Results: 1.After 9 months of follow-up,the average BCVA of group B significantly improved(P<0.05),from 0.50 logMAR(logarithm of the minimum resolution angle)to 0.15 logMAR,but the average BCVA of group A did not significantly improved(P>0.05).2.The baseline and the average BCVA of each follow-up were compared in pairs.The average BCVA of patients in group B increased significantly at 3rd,6th,and 9th month,and the difference was statistically significant(P<0.05);But the average BCVA of the patients in group A did not improve significantly at 3rd,6th and 9th month(P>0.05).3.In group B,the average BCVA between the three groups at at 3rd,6th,and 9th month was compared in pairs,and the difference was statistically significant(P<0.05);In group A,the average BCVA among the three groups at 3rd,6th and 9th month was compared in pairs.There was no significant improvement in average BCVA,and the difference was not statisticallysignificant(P>0.05).4.The baseline and the average CRT of each follow-up were compared in pairs.The average CRT of patients in groups A and B decreased significantly at the 3rd,6th,and 9th months,and the difference was statistically significant(P<0.05).5.In groups A and B,the average CRT between the three groups at month 3,month 6 and month 9 was compared in pairs.There was no significant improvement in average CRT,and the difference was not statistically significant(P>0.05);However,after 3 months of follow-up,the average CRT in group A showed a slow upward trend,and that in group B showed a slow downward trend.Conclusions: 1.With the development of treatment time,the visual response of PCV patients with choroidal vascular hyperpermeability to vitreous intravitreal injection of conbercept decreased gradually.2.In the first 3 months of a total of 3 injections once a month,conbercept can effectively reduce the central retinal thickness of polypoidal choroidal vascalopathy,and promote the absorption of retinal exudation and hemorrhage.However,after 3 injection treatments,the central retinal thickness of the polypoidal choroidal vascalopathy patients in the choroidal vascular hyperpermeability positive group showed a slow upward trend,while the negative group showed a slow downward trend.The general treatment response gradually decreased.